Amgen Posts Imdelltra Gains
I denne episoden
- Amgen Posts Imdelltra Gains
- Merck Reports Sac-TMT Survival
- J&J Sees Early Prostate Response
- Genmab Rina-S Tops Expectations
- FDA Approves Enspryng At Home
- EU Expands Teclistamab Use
Kilder
- BioSpace: ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
- STAT: STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
- BioSpace: ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
- Biopharminternational: Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer - BioPharm International
- BioSpace: ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda
- BioSpace: Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
- Pharmatimes: FDA approves Enspryng for at‑home TED treatment
- Pharmatimes: EU approves teclistamab monotherapy for earlier myeloma use
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.